Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)

This publication has 44 references indexed in Scilit:

• Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes
  PLOS ONE, 2013
• U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination
  New England Journal of Medicine, 2013
• Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial
  Clinical Infectious Diseases, 2013
• Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques
  PLOS ONE, 2013
• Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine
  Clinical and Vaccine Immunology, 2012
• Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
  Vaccine, 2011
• Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
  The Lancet Infectious Diseases, 2011
• The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
  Vaccine, 2011
• The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007
  Vaccine, 2010
• Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgary‐AreaStreptococcus pneumoniaeResearch (CASPER) Study
  Clinical Infectious Diseases, 2009